Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Overall, these results support the conclusion that the Nrf2 pathway is protective in a variety of kidney diseases.
|
27804998 |
2016 |
Kidney Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
4-O-methylhonokiol ameliorates type 2 diabetes-induced nephropathy in mice likely by activation of AMPK-mediated fatty acid oxidation and Nrf2-mediated anti-oxidative stress.
|
30876865 |
2019 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The protective effect of Nrf2 on renal injury has been attributed to its antioxidant role, where it aids in coping with oxidative stress-associated progression of renal disease.
|
31059771 |
2019 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Taken together, our study suggested that small-molecule Keap1-Nrf2 PPI inhibitors can activate the Nrf2-based cytoprotective system and protect the kidney from inflammatory injury, raising a potential application of Keap1-Nrf2 PPI inhibitors in the treatment of inflammatory kidney disorders.
|
31279986 |
2019 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
An increasing body of evidence supports a key role for Keap1/Nrf2 pathway in kidney diseases and renal cell carcinoma (RCC), but data concerning the molecular basis and the clinical effect of its deregulation remain incomplete.Here we present a molecular profiling of the KEAP1 and NFE2L2 genes in five different Renal Cell Carcinoma histotypes by analysing 89 tumor/normal paired tissues (clear cell Renal Carcinoma, ccRCCs; Oncocytomas; Papillary Renal Cell Carcinoma Type 1, PRCC1; Papillary Renal Cell Carcinoma Type 2, PRCC2; and Chromophobe Cell Carcinoma).A tumor-specific DNA methylation of the KEAP1 gene promoter region was found as a specific feature of the ccRCC subtype (18/37, 48.6%) and a direct correlation with mRNA levels was confirmed by in vitro 5-azacytidine treatment.
|
28061437 |
2017 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway is a well-established antioxidant pathway in various diseases such as diabetes, renal disease, various neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, etc.
|
29447051 |
2018 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.
|
28502971 |
2017 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Nrf2 Deficiency Upregulates Intrarenal Angiotensin-Converting Enzyme-2 and Angiotensin 1-7 Receptor Expression and Attenuates Hypertension and Nephropathy in Diabetic Mice.
|
29211853 |
2018 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, D‑pinitol increased the level of sirtuin 1 (Sirt1), and the total and nuclear expression levels of nuclear erythroid factor 2‑related factor 2 (Nrf2), suggesting that activation of the Sirt1 and Nrf2 pathways may induce the cellular antioxidant system against CsA‑induced nephropathy.
|
29393366 |
2018 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
We undertook a structured search of bibliographic databases for peer-reviewed research in literature about Nrf2 activators and renal disease.
|
28494744 |
2017 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In this review, we summarize recent literature investigating the role of NRF2 and oxidative stress in various kidney diseases, and how pharmacological modification of NRF2 signaling could play a protective role.
|
31372933 |
2020 |
Kidney Diseases
|
0.400 |
Therapeutic
|
group |
CTD_human |
Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity.
|
20605904 |
2010 |
Kidney Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
<b>Methods:</b> Electron microscopy, immunohistochemical (IHC) staining, Western blot, and real-time PCR were used to detect the expression of ACSL1and Nrf2 in ORN patients, ob/ob mice and palmitic acid (PA)-treated HK-2 cells.
|
31488013 |
2019 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in the African American Study of Kidney Disease (AASK).
|
23220723 |
2013 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, apocynin exerts antiseptic activity via the suppression of pro-inflammatory signaling pathways and the activation of cytoprotective signaling pathways, such as HO-1/Nrf-2 in RMCs, indicating that apocynin may present as a promising candidate for in vivo evaluation of a therapeutic agent for inflammation-associated renal disorders.
|
28791341 |
2017 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
This review summarizes the current issues in the treatment of kidney diseases, including clinical endpoints, Nrf2 activators as treatment options, and perspectives on pharmaceutical applications of Nrf2 activators.
|
30248418 |
2018 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The natural compound 2,3,5,4'-tetrahydroxystilbene-2-O-β-d glucoside protects against adriamycin-induced nephropathy through activating the Nrf2-Keap1 antioxidant pathway.
|
29064158 |
2018 |